HgCapital makes undisclosed investment in Evaluate
HgCapital announced an investment in Evaluate, a London-based provider of commercial intelligence to the global life sciences industry, on Tuesday.
Equity Investment Instruments
11,766.90
16:59 26/04/24
FTSE All-Share
4,423.59
17:14 26/04/24
FTSE Small Cap
6,484.28
16:59 26/04/24
HGCapital Trust
480.50p
16:35 26/04/24
The London-listed firm said the terms of this transaction have not been disclosed.
It said Evaluate is the trusted provider of mission critical commercial information for complex business decisions to the pharmaceutical industry.
Its core product is an “industry leading” set of analyst consensus forecasts that provides detailed insights at the product, disease, indication and geographic level.
It creates value by structuring, normalising and integrating data from company filings, research organisations, and government bodies and providing tools that drive analytical insights from data, HgCapital’s board explained.
The transaction represents the eleventh investment from the Mercury Fund and the fourth investment this year following other recent investments in Germany and France.
“We are delighted to be partnering with the team at Evaluate for the next phase of their journey, said director of HgCapital’s Mercury team David Issott.
“Evaluate represents exactly the type of investment opportunity that we raised Mercury to support: a founder entrepreneur looking for a value-add partner to help scale their business and fulfil its potential.
“We are also pleased to be making a second investment in healthcare IT, a core sub-sector for HgCapital.”
Jonathan de Pass, founder and chairman of Evaluate, said the HgCapital team impressed his company with its deep understanding of the market and business.
“The management team and I are delighted to be partnering with HgCapital to realise our strategy of becoming the recognised leader in commercial life sciences information and analytics.”